BioSpace News Archive

Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported fourth quarter and full year 2021 financial results and provided business highlights.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

argenx SE announced that the underwriters of its previously announced global offering of ordinary shares have exercised in full their option to purchase 350,000 additional ordinary shares in the form of ADSs on the same terms and conditions as the global offering.

RNAimmune, Inc. (the “Company” or “RNAimmune”), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US$27 million Series A round of financing.

Nipro Medical Corporation, a leading manufacturer and supplier of renal, vascular, and medical-surgical products, announces the commercial launch of SURDIAL™ DX Hemodialysis System to the U.S.

OSSIO, Inc. announced today that the company has achieved another significant commercial milestone with its third regulatory clearance from the U.S. Food and Drug Adminstration (FDA) for the OSSIOfiber® product family in the past four months, clearing a path to expand patient and surgeon access to additional implants made from OSSIOfiber® Intelligent Bone Regeneration Technology over the next six months.

Breast cancer is the world’s most commonly occurring cancer. According to Cancer.ca, breast cancer is the second leading cause of cancer deaths in Canadian women.

The global dental equipment market size is predicted to hit US$ 12.20 billion by 2029 and expected to drive growth at a CAGR of 8.7% from 2021 to 2030.

Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT).

The lyme disease diagnostic devices market to reach valuation US$ 3.87 billion by 2027 and is growing at a CAGR of 7.2% over the forecast period 2020 to 2027.